Biomarkers, inflammation, oxidative stress, lipids and atherothrombosis. Atherosclerosis:an inflammatory process

Jorge Carrillo Calvillo; Iván R Bear Sandoval

2004, Number s2

<< Back Next >>

Arch Cardiol Mex 2004; 74 (s2)

Biomarkers, inflammation, oxidative stress, lipids and atherothrombosis. Atherosclerosis:an inflammatory process

Carrillo CJ, Bear SIR

Full text

How to cite this article

Language: Spanish
References: 20
Page: 379-384
PDF size: 65.36 Kb.

ABSTRACT

Inflammation role in atherosclerosis has been well established during the past decade. From a pathological perspective, atherosclerosis may be regarded as an inflammatory response to damage. Risk factors promote monocyte adhesion to endothelial cells and its migration in the subintimal space. Lipoproteins oxidation and release of other substances from activated macrophages may break collagen strands and may lead to plaque rupture.

REFERENCES

Libby P, Ricker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
Gimbrone MA Jr, Cybulsky MI, Kume N, Collins T, Resnick N: Vascular endothelium: an integrator of pathophysiological stimuli in atherogenesis. Ann NY Acad Sci 1995; 748: 122-132.
De Caterina R, Libby P, Peng H-B, et al: Nitric Oxide decreases cytokine-induced endothelial activation: nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 1995; 96: 60-68.
Gerszten RE, Mach F, Sauty A, Rosenzweig A, Luster AD: Chemokines leukocytes, and atherosclerosis. J Lab Clin Med 2000; 136: 87–92.
Qiao J-H, Tripathi J, Mishra NK, et al: Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am J Pathol 1997; 150: 1687-1699.
Jhon S, Schmieder RE: Impaired endothelial function in arterial hypertension and hipercholesterolemia: potential mechanisms and differences. J Hypertens 2000; 18: 363-374.
Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P: The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Eng J Med 1995; 332: 488-93.
Valkonen V-P, Pavia H, Salonen JT, et al: Risk of acute coronary events and serum concentrations of asymmetrical dimethylarginine. Lancet 2001; 358: 2127-2128.
Beckman KB, Ames BN: The Free Radical Theory of Aging Matures. Am Physiol Soc. 1998; 78: 547-581.
Collins T, Cybulsky MI: NFkB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 2001; 107: 255-264.
Libby P: Changing concepts in atherogenesis. J Intern Med 2000; 247: 349-358.
Mach F, Schonbeck U, Libby P: CD40 signaling in vascular cells: a key role in atherosclerosis? Atherosclerosis 1998; 137 (suppl): S89-S95.
Beckman JA, Creager MA, Libby P: Diabetes and athersclerosis: epidemiology, phatology, and management. JAMA 2002; 287: 2570-2581.
de Beer FC, Hind CR, Fox KM, et al: Measuremeant of C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J 1982; 47: 239-243.
Berk BC, Weintraub WS, Alexander RW: Elevation of C-reactive protein in “active” coronary artery disease. Am J Cardiol 1990; 65: 168-172.
Luizzio G, Biasucci LM, Gallimore JR, et al: The prognostic value of C-reactive protein in severe unstable angina. N Engl J Med 1997; 331: 417-424.
Ridker PM, Cushman M, Stampfer MJ, et al: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthily men. N Engl J Med 1997; 336: 973-979.
Chew DP, Deepak LB, Robins MA, et al: Incremental Prognostic Value of Elevated Baseline C-reactive Protein Among Established Markers of Risk In Percutaneous Coronary Intervention. Circulation 2001; 104: 992-997.
Hojo Y, Ikeda U, Mizuno O, et al: Interleukin-6 expression in coronary after coronary angioplasty as a risk factor for restenosis. Heart 2000; 84: 83-87.
Heeschen C, Dimmeler S, Hamm CW, et al: Serum level of the Anti-inflammatory Cytokine Interleukin-10 Is an important Prognostic Determinant in Patients With Acute Coronary Syndromes. Circulation 2003; 107: 2109-2114.